Program Description: 

This educational activity is designed to incorporate evidence-based pathophysiology, diagnosis, and/or treatment of urologic disorders into clinical practice. Speakers will utilize their personal, institutional and evidence-based experience to address patient health care conditions requiring clinical and surgical treatment.  Speakers will also utilize departmental quality improvement data, M&M data, and patient safety data to improve outcomes of urologic disease and other aspects of urologic  patients’ general health. Evidence-based data regarding the changing aspects/newer approaches to surgical disease will be analyzed, and critical issues related to urology within the broader scope of American health care will be discussed.  There are varying degrees to individuals’ knowledge regarding clinical and urologic treatments.  While individuals may be aware of varied treatment within the urologists’ armamentarium it is beneficial to address the topics from an evidence-based approach.

Target audience: 
  • Physicians                       
  • Physician (fellows/residents)        
  • Physician Assistants 
  • Nurse Practitioners
  • AP/NP
  • Nurses       
Learning objectives: 

Participants who engage in this educational intervention will be able to:

1. To learn about standard of care treatment of high risk Non-Muscle Invasive Bladder Cancer

2. To learn about alternative therapies of high risk Non-Muscle Invasive Bladder Cancer

3. To learn about alternative treatment options to BCG for high risk Non-Muscle Invasive Bladder Cancer

Faculty & credentials: 

In accordance with the ACCME® Standards for Commercial Support Six, all in control of content must disclose any relevant financial relationships. The following in control of content had no relevant financial relationships to disclose.

  • Kenneth Jacobsohn, MD

  • Gary Steinberg, MD has disclosed that he has commercial interests: as a member of Clinical Trial Protocol Committees for the following companies: Merck, BMS, Janssen, Cold Genesys, Pfizer, PhotoCure, Fidia I am or have been a scientific advisor/consultant within the past 5 years for the following companies: Heat Biologics; CG Oncology; PhotoCure; Merck; Roche/Genentech; Ciclomed; Taris Biomedical (Now Janssen); MDxHealth; Fidia Farmaceuticals; Urogen,  Ferring; Aduro; Boston Scientific; Bristol Myers Squibb; Astra Zeneca; Pfizer, Janssen;  Epivax Therapeutics; Natera; FKD; EnGene Bio; SesenBio; BioCanCell (Now Archiano); Nucleix; Ipsen; Combat Medical; Astellas;  Fergene; Dendreon; Abbvie; Seattle Genetics; Verity Pharmaceuticals, Regeneron

    He has equity stock/options: Epivax Therapeutics, Urogen

 

Presenter:
Gary Steinberg, MD

Professor and Director of the Goldstein Urology Bladder Cancer Program, NYU Langone Health, New York, NY

Contact

Name: 
Tammy Janik
Phone number: 
+1 (414) 955-0880
Email: 
tjanik@mcw.edu

ACCME Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement:
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

Session date: 
06/18/2021 - 7:00am to 8:00am CDT
Location: 
Medical College of Wisconsin Virtual Meeting via Zoom
Milwaukee, WI 53226
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Please login or register to take this course.